Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Rapid advances in medical science are bringing an astonishing array of new therapies to patients. At the same time, those advances raise significant questions about how to strike an appropriate balance between patient safety and the availability of potentially lifesaving drugs and medical devices. In its recent decision in Riegel v. Medtronic Inc., the U.S. Supreme Court delved into the thorny issue of who is best positioned to weigh the benefits and costs of new treatments and reconcile the interest in protecting public safety with the sometimes competing interest in protecting the market for new devices. At issue in this case was the meaning of the so-called pre-emption clause contained in the Medical Device Amendments (MDA) to the Federal Food, Drug and Cosmetic Act, which created the federal regulatory system for medical devices. That clause bars any state from establishing a requirement for a device “which is different from, or in addition to, any requirement” established under the MDA. Specifically, the court addressed the issue of whether the clause precludes consumers from bringing state personal injury suits challenging the safety and efficacy of a very small number (roughly 1%) of the most sophisticated devices that receive Food and Drug Administration (FDA) “premarket approval.” The case originated in 1996 when an FDA-approved balloon catheter burst while Charles Riegel was undergoing an angioplasty. As a result, Riegel suffered a complete heart blockage, necessitating emergency coronary bypass surgery. Riegel later sued Medtronic Inc., the manufacturer of the catheter, claiming that the device was negligently designed, manufactured and mislabeled under New York state law. The U.S. district court dismissed most of Riegel’s claims on the ground that they were pre-empted by the MDA. The 2d U.S. Circuit Court of Appeals upheld that ruling, and the case was appealed to the Supreme Court. At one level, the Supreme Court decision in the case turned on the question of what constitutes federal and state requirements under the MDA. In denying Riegel’s claims against Medtronic, the court asserted that the catheter had been subject to an intensive approval process resulting in detailed federal requirements relating to the design, manufacture and labeling of the device. And, following its own reasoning in a prior pre-emption decision involving the MDA ( Medtronic v. Lohr), the court asserted that a successful state tort suit would effectively impose separate and competing design, manufacturing and labeling requirements on manufacturers of medical devices. Who should judge the design? But the court’s analysis ran deeper, to a consideration of whether the FDA or a state court was best suited to realize the public good of having available safe and effective medical devices. Medtronic’s balloon catheter was subject to an exhaustive premarket approval (PMA) process, under which manufacturers submit results of clinical studies and other extensive documentation for FDA review. Further, a device company submits an application for PMA typically only after investing thousands of hours and millions of dollars in developing and testing its new device. In turn, the FDA’s internal scientists and engineers spend on average 1,200 hours assessing the device, may refer the application to a panel of outside experts and frequently request additional data from the manufacturer before granting PMA. The idea that a jury of six or 12 laypeople is better positioned to render a decision about the appropriate design and labeling of a complex medical device based upon evidence involving a single plaintiff presented during a two- to three- week period, rather than scores of FDA experts assessing evidence involving hundreds of patients culled from multiyear clinical trials, defies all logic. As Justice Antonin Scalia, who wrote the court’s 8-1 opinion, stated during oral arguments in Riegel, “because of the judgment of that one jury, the manufacturer is placed at risk in selling a device that scientists at the FDA have said is okay. I find that extraordinary.” The Supreme Court’s ruling also recognizes that the environment in which medical device companies operate has changed dramatically since Congress passed the MDA in 1976. The number of suits against device manufacturers has proliferated, and Internet advertising has greatly aided well-financed plaintiffs’ attorneys in “collecting” unrelated clients for so-called “mass tort” litigation. Absent federal pre-emption, companies could face verdicts dictating design, manufacturing and labeling standards that differ in each of the 50 states � hardly a formula for bringing safe and effective devices to a national market. The FDA-centered process for approving new devices and drugs may not be perfect. But because the FDA does not always make the right judgment doesn’t justify allowing litigants to effectively set up an alternative regulatory process through the courts. Before Congress jumps to amend the MDA to overturn the court’s decision, its time would be better spent addressing funding deficiencies at the FDA and strengthening the FDA’s resources for reviewing new devices. But surely the proper remedy for an overworked FDA is not empowering a panel of ordinary citizens to make complex scientific judgments based upon a cursory review of a narrow band of evidence. David Ferrera is a partner at Boston-based Nutter McClennen & Fish, whose practice focuses on complex civil disputes, with an emphasis on drug and medical device litigation.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.